...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >Perioperative antiplatelet therapy: a knife-edged choice between thrombosis and bleeding still based on consensus rather than evidence.
【24h】

Perioperative antiplatelet therapy: a knife-edged choice between thrombosis and bleeding still based on consensus rather than evidence.

机译：围手术期抗血小板治疗：血栓形成和出血之间的刀口选择仍然基于共识而不是证据。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The number of patients receiving antipla-telet therapy, including combination aspirin plus a P_2Y_12 inhibitor, is increasing. Also increasing is the number of surgical procedures done around the world, with approximately 250 million people undergoing major surgery each year (1). A growing proportion (>40%) of these are elderly, and many receive anti-platelet therapy. In patients at risk for coronary artery disease undergoing surgery, myocardial infarction (MI) is the most common (6%) cardiovascular complication and this has a mortality rate of 15% to 25% (2). The cost of peri-operative cardiac events is estimated at dollar20 billion annually in the United States alone (2).
机译：接受抗阿片类药物治疗（包括阿司匹林加P_2Y_12抑制剂联合治疗）的患者人数正在增加。此外，世界范围内进行的外科手术数量也在增加，每年约有2.5亿人接受大手术（1）。其中越来越多的人（> 40％）是老年人，并且许多人接受抗血小板治疗。在有患冠状动脉疾病手术风险的患者中，心肌梗塞（MI）是最常见的心血管并发症（6％），其死亡率为15％至25％（2）。仅在美国，围手术期心脏事件的成本估计每年就达200亿美元（2）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号